IL16

Across TCGA pan-cancer cohorts, IL16 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IL16 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher IL16 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IL16 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

COAD, LUAD, and PDAC are the cancer types where IL16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Quartile	All	0.848	1.000	.021	42	view →
LUAD	DFS	Median	All	0.793	0.478	<.001	35	view →
PDAC	DFS	Median	All	0.904	0.683	.001	23	view →
CCRCC	OS	Median	II,III,IV	0.834	0.618	.003	15	view →
HNSC	DFS	Median	All	0.921	0.980	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IL16–COAD (DFS)

Open the COAD breakdown →